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A new study by Arany et al. demonstrates that the metabolic master regulator peroxisome proliferator-
activated receptor (PPARg) coactivator-1a (PGC-1a) can promote angiogenesis. These findings show that
alterations inmetabolic homeostasis are linked to angiogenesis, which raises exciting opportunities for novel
proangiogenic and antiangiogenic therapies in various diseases.Blood vessels carry oxygen and nutrients
to distant cells in the body. When oxygen
is plentiful, most cells use oxygen for
generating energy, as its reduction pro-
vides the largest free energy release per
electron transfer. However, when the sup-
ply of blood is limiting, for example due
to occlusion by a clot, cells switch from
aerobic to anaerobic metabolism, which
is less efficient and often insufficient.
Therefore, mechanisms, such as the stim-
ulation of angiogenesis, must be in place
to restore the supply of oxygen and nutri-
ents. In a recent study in Nature, Arany
et al. (2008) report that PGC-1a, a master
regulator of oxidative metabolism, upre-
gulates the release of vascular endothelialgrowth factor (VEGF), a key
angiogenic factor. This mo-
lecular link ensures that con-
sumption of oxygen by oxida-
tive metabolism remains in
close balance with supply of
oxygen through angiogenesis
to meet the metabolic needs
of tissues (Figure 1).
Induced by variations in
energy homeostasis, PGC-
1a switches on gene regula-
tory programs that allow the
organism to meet diverse
physiological anddietary con-
ditions (FinckandKelly, 2006).
As a coactivator, PGC-1a
boosts the transcriptional ac-
tivity of nuclear receptors
that relay physiological and
nutritional cues to critical
gene regulatory responses.
In skeletal muscle and theheart, PGC-1a augments energy produc-
tion by stimulating processes such as
mitochondrial biogenesis and cellular res-
piration (Finck and Kelly, 2006). Overall,
PGC-1a acts as apotentmetabolic sensor
that promotes oxidative metabolism.
Arany and coworkers report that
hypoxia, especially in combination with
nutrient deprivation, upregulates the
expression of PGC-1a. This is, at first
sight, a paradox, as PGC-1a stimulates
oxygen consumption, which would only
further aggravate cellular hypoxia. How
could a shortage of oxygen be compatible
with a cell’s response to increase utiliza-
tion of oxygen? The organism’s response
to deprivation of oxygen, nutrients, orDevelopmental Cboth actually involves additional players.
Indeed, in response to a shortage of
oxygen, hypoxia-inducible transcription
factors (HIFs) activate gene regulatory
programs that, among others, induce an
acute shift fromoxidative to glycolyticme-
tabolism to conserve oxygen (Semenza,
2003). But, at the same time, and in an
effort to restore tissue oxygenation, HIFs
upregulate the expression of the angio-
genic factor VEGF and that of other sig-
nals; together, this results in processes
such as angiogenesis, vasodilation, and
erythropoiesis, which increase the deliv-
ery of oxygen (Carmeliet, 2000; Semenza,
2003). PGC-1a boosts this hypoxia-
induced angiogenic response by furtherell 14, Marchinducing the expression of
VEGF, not through canonical
HIF pathways, but through
estrogen-related receptor-a
(ERR-a), an orphan nuclear
receptor and well-known
partner of PGC-1a. Thus, in
anticipation of a more oxida-
tivemetabolism,PGC-1apro-
motes a more efficient supply
of oxygen by stimulating
VEGF-driven angiogenesis.
Is the induction of VEGF by
PGC-1a also sufficient to
mount a relevant angiogenic
response? Arany et al. tested
this hypothesis by using mice
overexpressing or lacking
PGC-1a. Forced expression
of PGC-1a in skeletal muscle
upregulated VEGF levels and
stimulated capillary angio-
genesis 3-fold in healthyFigure 1. PGC-1a Stimulates Metabolism by Promoting
Angiogenesis
Physiological or pathological (e.g., vessel occlusion, black bar) conditions can
cause a drop in oxygen supply (blue dots) and nutrient supply (orange dots) to
tissues, which can hamper themetabolic activity of cells (blue). This causes the
induction of PGC-1a, which upregulates VEGF to stimulate angiogenesis,
thereby accelerating the availability of oxygen and nutrients and hence the
metabolic activity of cells (red). Thus, PGC-1a couples oxygen supply to
oxygen utilization.2008 ª2008 Elsevier Inc. 313
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PGC-1a in athletes upon endurance train-
ing are accompanied with an increase in
vascularization of red muscle fibers. Con-
versely, loss of PGC-1a does not affect
baseline expression of VEGF and does
not appear to cause vascular defects in
development, perhaps because organs,
such as the heart, switch to intense oxi-
dative metabolism only after birth. Inter-
estingly, loss of PGC-1a aggravates re-
vascularization of the ischemic limb,
whereas overexpression of PGC-1a has
the opposite effect. PGC-1a thus con-
tributes to the angiogenic switch in path-
ological, but not in physiological, condi-
tions. Such disease-specific angiogenic
regulators are attractive drug targets be-
cause of a greater safety profile.
PGC-1a’s activity profile in stimulating
oxygen supply (angiogenesis) and oxygen
utilization (oxidative metabolism) is not
unique. In fact, other regulators partici-
pate in this angiogenesis/metabolism
link. For instance, AMP-dependent kinase
(AMPK) senses energy deprivation; acti-
vation of this metabolic master switch
stimulates fuel utilization as well as
angiogenesis through stimulating VEGF
expression (Ouchi et al., 2005). Another
example is PPARb, which promotes blood
vessel maturation (Piqueras et al., 2007).
SIRT1—a homolog of the histone de-
acetylase Sir2, whose activity depends
on the availability of NAD+ and thus on
themetabolic status of the cell—enhances
the activity of several metabolic regula-
tors, such as PGC-1a, through deacetyla-
tion. SIRT1 is expressed in the vasculature
and stimulates angiogenesis, even though
it remains unknownwhether this effect de-
pends on PGC-1a (Potente et al., 2007).
However, not all metabolic regulators314 Developmental Cell 14, March 2008 ª20that influence oxidative metabolism stim-
ulate angiogenesis. For instance, PPARg
and PPARa lower the expression of VEGF
in tumors and VEGF receptor-2 in endo-
thelial cells, respectively, while upregulat-
ing the angiogenesis inhibitor thrombo-
spondin-1 (Panigrahy et al., 2002, 2008).
Other regulators such as the oxygen
sensor PHD1 regulate hypoxia tolerance
(hibernation) via reprogramming oxygen
consumption without altering angiogene-
sis (Aragones et al., 2008). Taken together,
metabolic regulators control angiogenesis
either directly, by modifying the expres-
sion of proangiogenic or antiangiogenic
factors, or indirectly, by regulating endo-
thelial cell responses to these angiogenic
signals.
As is often the case with scientific
breakthroughs, this raisesmore questions
than it provides answers. For instance,
hypoxia upregulates the expression of
PGC-1a, but independent of the canoni-
cal HIF pathway: which oxygen-sensing
pathways are involved? Since PGC-1a
upregulates various angiogenic factors,
it could stimulate a more mature and sta-
ble (and hence better) perfused vascular
network. But, considering the risk of
cardiomyopathy in mice overexpressing
PGC-1a, titration of its levels seems man-
datory. Conversely, will PGC-1a inhibitors
be useful to inhibit vessel growth in
tumors and ocular disease, without caus-
ing adverse effects on metabolism of
these cells? And, does hypoxic upregula-
tion of PGC-1a also stimulate angiogene-
sis and oxidative metabolism of tumor
cells that rely largely on glycolytic metab-
olism? If cells sense their environment for
nutrient availability and metabolic de-
mand, and initiate changes to promote
or restrict nutrient availability by flicking08 Elsevier Inc.the angiogenic switch, what then hap-
pens to angiogenesis in metabolic disor-
ders, such as obesity and diabetes?
Also, will a cell facing nutritional overload
reduce its supply by reducing vessel
growth, and does this contribute to com-
plications of metabolic disorders? The
exciting findings by Arany et al. open the
gates to merge two areas of research
that are likely much more closely inter-
twined than originally anticipated.
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